Market Overview

UPDATE: Piper Jaffray Upgrades Alnylam Pharmaceuticals to Overweight; Overhang Removed

Related ALNY
The Biotech Stock With The Biggest Head Of Steam
Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Piper Jaffray raised its rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight and increased its price target from $19 to $25.

Piper Jaffray noted, "With the Tekmira litigation behind them, Alnylam can now focus on RNAi clinical progress and partnerships in 2013. Specifically, we look forward to Phase II ALN-TTR02 data this summer to prepare the company for pivotal studies by year-end. We also expect Alnylam to file INDs on sub-cutaneous formulations of ALN-TTR02 and ALN-AT3, an innovative hemophilia therapy. We also look for Alnylam to continue to partner its RNAi therapeutic pipeline, most importantly ALN-PCS to lower cholesterol."

Alnylam Pharmaceuticals closed at $17.99 on Tuesday.

Posted-In: Piper JaffrayAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters